Back to search results

Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia

Abroad (travel likely)RecruitingPHASE1

Conditions

Relapsed Myelodysplastic Syndrome · Refractory Myelodysplastic Syndrome · Acute Myeloid Leukemia · Recurrent Acute Myeloid Leukemia · Refractory Acute Myeloid Leukemia

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Baptist Health Care Corporation, Memphis, Tennessee, United States

    Contact: Study coordinator (Salil Goorha) · salil.goorha@bmhcc.org

  • Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States

    Contact: Study coordinator (Vanderbilt-Ingram Service Services for Timely Access) · cip@vumc.org · 800-811-8480
    Contact: Principal Investigator (Somedeb Ball, MD)
Study leads

  • Somedeb Ball, MD

    Principal Investigator

    Vanderbilt University/Ingram Cancer Center

View source on ClinicalTrials.gov(opens in a new tab)